Improving Hemocompatibility with RAAS Inhibition

Managing advanced heart failure often requires the use of a durable left ventricular assist device (LVAD). While devices like the HeartMate 3 have revolutionized outcomes, hemocompatibility-related adverse events (HRAE) remain a significant challenge. However, a recent secondary analysis of the MOMENTUM-3 trial suggests that RAAS inhibition in LVAD therapy may play a pivotal role in reducing these complications. Researchers evaluated 1,855 clinically stable patients to determine if renin-angiotensin-aldosterone system inhibition (RAASi) correlates with a lower burden of adverse events.

Impact of RAAS Inhibition in LVAD on Bleeding Outcomes

The study specifically looked at patients who were initiated on RAASi therapy within one month of device implantation. Consequently, the results demonstrated that RAASi exposure was associated with a significant 17% reduction in the composite rate of hemocompatibility-related adverse events over two years. The primary driver of this benefit was a decrease in non-surgical bleeding events. Specifically, the adjusted rate ratio for bleeding was 0.82, indicating an 18% lower risk for those on therapy. Furthermore, the clinical benefit was even more pronounced among patients who maintained sustained exposure to these medications, showing a 33% reduction in adverse events.

The biological rationale for these findings centers on the suppression of chronic neurohormonal activation. Continuous-flow support can lead to vascular maladaptation and the development of arteriovenous malformations, which frequently cause mucosal bleeding. Because RAAS inhibitors modulate pathways involving vascular endothelial growth factor (VEGF) and angiopoietin, they may stabilize the microvasculature. Moreover, this therapy appears to improve overall survival, making it a cornerstone of post-implant management. Therefore, clinicians should prioritize the early initiation and maintenance of RAASi in stable LVAD recipients to optimize long-term hemocompatibility.

Practical Implications for Heart Failure Management

In the Indian clinical context, where heart failure management is evolving rapidly, these insights are invaluable. Since mucosal bleeding often necessitates hospital readmissions and blood transfusions, implementing RAASi can reduce the overall healthcare burden. Additionally, the consistency of these findings across different patient subgroups highlights the broad applicability of neurohormonal blockade in mechanical circulatory support. Consequently, integrating RAAS inhibition into standard post-LVAD protocols is recommended to enhance patient quality of life and device longevity.

Frequently Asked Questions

How does RAAS inhibition specifically help LVAD patients?

RAAS inhibition helps by reducing the neurohormonal activation that occurs during continuous-flow support. This reduces vascular remodeling and inhibits maladaptive angiogenesis, which are the primary causes of non-surgical mucosal bleeding in these patients.

When should RAAS inhibitors be initiated after LVAD surgery?

The study found significant benefits when patients were started on therapy within the first month after implantation. However, initiation depends on clinical stability and the patient’s ability to tolerate the hemodynamic effects of the medication.

Does RAASi therapy affect survival in LVAD recipients?

Yes, the MOMENTUM-3 analysis indicated that RAASi therapy was associated with higher overall survival rates at the two-year mark, likely due to the combined reduction in bleeding complications and improved cardiac remodeling.

Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Isath A et al. Renin-angiotensin-aldosterone system inhibition and haemocompatibility-related adverse events in patients with durable left ventricular assist device: the MOMENTUM-3 trial . Eur Heart J. 2026 May 10. doi: undefined. PMID: 42106929.

Mehra MR, et al. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med. 2019;380(17):1618-1627.

Houston BA, et al. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. J Heart Lung Transplant. 2017;36(4):380-385.